NCT02601859View on ClinicalTrials.gov

Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Lithium Carbonate

All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

University of Dundee

OTHER

NCT02601859 - Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter